World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
84
Citations
41359
World Ranking
1336
National Ranking
686

Medicine

D-Index
84
Citations
41448
World Ranking
14840
National Ranking
7501

Renier J. Brentjens publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Renier J. Brentjens sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 325 publications — 69th percentile

69% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Renier J. Brentjens D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Renier J. Brentjens sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 84 D-Index — 73rd percentile

73% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Renier J. Brentjens is affiliated with the Roswell Park Cancer Institute in the United States. Their research primarily centers on the field of medicine, with a strong focus on oncology and immunology. The scientist's body of work spans molecular biology, genetics, and electrical and electronic engineering, demonstrating a multidisciplinary approach to biomedical challenges.

The main topics of Renier J. Brentjens' research include:

  • CAR-T cell therapy research
  • Immune Cell Function and Interaction
  • Viral Infectious Diseases and Gene Expression in Insects
  • Immunotherapy and Immune Responses
  • Virus-based gene therapy research
  • Nanowire Synthesis and Applications
  • Cancer Immunotherapy and Biomarkers

Among their recent publications are significant contributions to the field of CAR-T cell therapy and immunotherapy:

  • "A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab" (2021, Cancer Discovery)
  • "GPRC5D-Targeted CAR T Cells for Myeloma" (2022, New England Journal of Medicine)
  • "Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion" (2022, Nature Reviews Clinical Oncology)
  • "Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy" (2022, Nature Medicine)
  • "Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies" (2020, Blood Advances)

Renier J. Brentjens has a consistent publication record in high-impact journals and specialized venues including:

  • Blood
  • Cancer Immunology Research
  • Nature Medicine
  • Blood Advances
  • Journal for ImmunoTherapy of Cancer

The scientist collaborates frequently with peers such as Jae H. Park, Isabelle Rivière, Michel Sadelain, Sergio Giralt, and Craig S. Sauter, reflecting an active engagement in advancing cancer immunotherapy research through teamwork.

Best Publications

  • Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

    Marco L. Davila;Isabelle Riviere;Xiuyan Wang;Shirley Bartido

  • Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

    Jae H. Park;Isabelle Rivière;Mithat Gonen;Xiuyan Wang

  • CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

    Renier J. Brentjens;Marco L. Davila;Isabelle Riviere;Jae Park

  • The Basic Principles of Chimeric Antigen Receptor Design

    Michel Sadelain;Renier Brentjens;Isabelle Rivière

  • Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

    Renier J. Brentjens;Isabelle Rivière;Jae H. Park;Marco L. Davila

  • The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

    Danny N. Khalil;Eric L. Smith;Renier J. Brentjens;Jedd D. Wolchok

  • Engineering strategies to overcome the current roadblocks in CAR T cell therapy

    Sarwish Rafiq;Christopher S. Hackett;Renier J. Brentjens

  • Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.

    John Maher;Renier J Brentjens;Gertrude Gunset;Isabelle Rivière

  • Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.

    Renier J. Brentjens;Jean Baptiste Latouche;Elmer Santos;Francesc Marti

  • Toxicity and management in CAR T-cell therapy.

    Challice L Bonifant;Hollie J Jackson;Renier J Brentjens;Kevin J Curran

  • Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning

    Hollie J. Pegram;James C. Lee;Erik G. Hayman;Gavin H. Imperato

  • Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.

    Bianca D. Santomasso;Jae H. Park;Darin Salloum;Isabelle Riviere

  • Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

    Sarwish Rafiq;Oladapo O Yeku;Hollie J Jackson;Terence J Purdon

  • The promise and potential pitfalls of chimeric antigen receptors

    Michel Sadelain;Renier Brentjens;Isabelle Rivière

  • Targeting tumours with genetically enhanced T lymphocytes

    Michel Sadelain;Isabelle Rivière;Renier Brentjens

  • Driving CAR T-cells forward

    Hollie J. Jackson;Sarwish Rafiq;Renier J. Brentjens

  • Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts

    Renier J. Brentjens;Elmer Santos;Yan Nikhamin;Raymond Yeh

  • Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial

    Renier Brentjens;Raymond Yeh;Yvette Bernal;Isabelle Riviere

  • Tumor Targeting with Antibody-Functionalized, Radiolabeled Carbon Nanotubes

    Michael R. McDevitt;Debjit Chattopadhyay;Barry J. Kappel;Jaspreet Singh Jaggi

  • A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab.

    Prasad S. Adusumilli;Marjorie G. Zauderer;Isabelle Rivière;Stephen B. Solomon

  • Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy.

    Daniel Hollyman;Jolanta Stefanski;Mark Przybylowski;Shirley Bartido

Frequent Co-Authors

Michel Sadelain
Michel Sadelain Columbia University
Isabelle Riviere
Isabelle Riviere Memorial Sloan Kettering Cancer Center
Sergio Giralt
Sergio Giralt Memorial Sloan Kettering Cancer Center
Miguel-Angel Perales
Miguel-Angel Perales Memorial Sloan Kettering Cancer Center
Nancy A. Kernan
Nancy A. Kernan Memorial Sloan Kettering Cancer Center
Richard J. O'Reilly
Richard J. O'Reilly Memorial Sloan Kettering Cancer Center
David A. Scheinberg
David A. Scheinberg Memorial Sloan Kettering Cancer Center
Marcel R.M. van den Brink
Marcel R.M. van den Brink Memorial Sloan Kettering Cancer Center
Mithat Gonen
Mithat Gonen Memorial Sloan Kettering Cancer Center
Steven M. Larson
Steven M. Larson Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology in the USA opens doors to diverse healthcare careers, many of which can be enhanced through online education. For nurses and healthcare professionals, pursuing advanced degrees is a strategic way to deepen expertise and improve earning potential. Interested students can explore online accelerated nursing programs for non nurses, which offer a fast-track route into the nursing field without prior nursing experience.

For registered nurses ready to advance, accelerated RN to NP programs provide a compact timeframe to become nurse practitioners, significantly expanding career options. Additionally, existing family nurse practitioners (FNPs) may consider gaining specialized skills with an acute care certification for FNP, adapting their practice to acute and critical care settings.

Understanding salary prospects can help shape career decisions. Exploring the DNP salary across different states reveals variations that impact financial planning and job market choices. Together, these pathways reflect the evolving landscape of healthcare careers linked to immunology expertise.

Best Scientists Citing Renier J. Brentjens

Trending Scientists

Recently Published Articles